ABUS
Arbutus Biopharma Corporation
ABUS has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over ABUS overall, supported by stronger modeled upside.
ABUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Unavailable |
ABUS's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.6x | $4.03 | — |
| Cheap | 5.2x | $5.83 | +45% |
| Fair | 5.5x | $6.20 | +54% |
| Expensive | 6.3x | $7.07 | +75% |
Historical ranges are pointers, not guarantees.
ABUS has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ABUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ABUS's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ABUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.13 | +$1.36 |
| Q2 2026 | $0.79 | +$1.08 |
| Q1 2026 | $0.83 | +$1.24 |
| Q4 2025 | -$0.17 | +$0.21 |
| Q3 2025 | -$0.23 | +$0.20 |
| Q2 2025 | -$0.29 | +$0.16 |
| Q1 2025 | -$0.41 | +$0.03 |
| Q4 2024 | -$0.38 | +$0.06 |
ABUS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ABUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299K | -43% |
| Q2 2026 | $1M | -91% |
| Q1 2026 | $179.1M | +10055% |
| Q4 2025 | $1.1M | -33% |
| Q3 2025 | $529K | -60% |
| Q2 2025 | $10.7M | +522% |
| Q1 2025 | $1.8M | +15% |
| Q4 2024 | $1.6M | -27% |
ABUS's revenue is growing: $299,000 last quarter, down 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3510% | -1873 points |
| Q2 2026 | -588% | -602 points |
| Q1 2026 | 94% | +1551 points |
| Q4 2025 | -503% | +382 points |
| Q3 2025 | -1637% | -36 points |
| Q2 2025 | 14% | +1264 points |
| Q1 2025 | -1457% | -193 points |
| Q4 2024 | -885% | +82 points |
ABUS's operating margin was −3510% last quarter, down 1873 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ABUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ABUS on profitability, with a higher operating margin.
ABUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $239.8M | +$245.6M |
| Q2 2026 | -$6M | +$9.7M |
| Q1 2026 | -$8.1M | +$5.3M |
| Q4 2025 | -$4.7M | +$5.7M |
| Q3 2025 | -$5.8M | +$14.9M |
| Q2 2025 | -$15.7M | -$1.2M |
| Q1 2025 | -$13.4M | +$6M |
| Q4 2024 | -$10.4M | +$6.9M |
ABUS has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ABUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +2.2M shares |
| 1 year | +4.1% | +7.8M shares |
| 3 years | +19% | +32.1M shares |
| 5 years | +106% | +103M shares |
| Available history | +190% | +131M shares |
ABUS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ABUS Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ABUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 12.4 | Oversold |
ABUS's weekly RSI is 42 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ABUS PE vs Healthcare Sector
| Metric | ABUS | Sector median | Relative |
|---|---|---|---|
| PE | 3.6x | 26x | 86% below |
| PE % | 0 | 29 | 29 pts below |
ABUS has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ABUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 4.7% below |
| 20 week MA | $4.58 | 12% below |
| 50 week MA | $4.45 | 9.4% below |
| 100 week MA | $4.03 | 0% above |
| 200 week MA | $3.43 | 17% above |
ABUS has fallen below most of its moving averages, though it's still 17% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ABUS on trend strength, trading above more of its moving averages.
ABUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.49 | $3.87 | +55% |
| 2021 | $3.87 | $4.16 | +7.5% |
| 2022 | $4.16 | $2.39 | -43% |
| 2023 | $2.39 | $2.50 | +4.6% |
| 2024 | $2.50 | $3.21 | +28% |
| 2025 | $3.21 | $4.78 | +49% |
| 2026 YTD | $4.78 | $4.03 | -16% |
ABUS has finished higher in five of the last six years. It's down 16% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ABUS on returns for 2026, with the stronger performance.